Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial - PubMed
6 hours ago
- #targeted therapy
- #HER2-positive breast cancer
- #clinical trial
- The phase 3 PHILA trial evaluated pyrotinib or placebo combined with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
- 590 untreated HER2-positive metastatic breast cancer patients were randomized to receive pyrotinib or placebo alongside trastuzumab and docetaxel.
- Pyrotinib group showed longer overall survival (HR 0.64, P=0.004) and progression-free survival (22.1 vs. 10.5 months, HR 0.44, P<0.001) compared to placebo.
- Safety profiles remained consistent with no new safety signals identified during extended follow-up.
- The trial confirmed the efficacy of pyrotinib plus trastuzumab as an effective initial treatment for HER2-positive metastatic breast cancer.